Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Dec;12(9):667-75.
doi: 10.1097/00008571-200212000-00001.

Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients

Affiliations
Review

Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients

Sandrine de Montgolfier et al. Pharmacogenetics. 2002 Dec.

Abstract

The aim of this study was to analyse ethical issues concerning the storage of human biological samples to be used in genetic analyses and pharmacogenetic research based on a French experience of DNA banking in a cohort of human immunodeficiency virus (HIV)-infected patients started on a protease inhibitor-containing treatment. We describe the ethical issues raised during the establishment of a DNA bank, including questions dealing with autonomy, benefit to the patient, information sharing and confidentiality as well as guarantees concerning the storage and use of DNA. The practical applications of themes illustrated theoretically in the literature are discussed. Most of the points raised are not specific to HIV, but some of them may be more accurate due to the characteristics of the HIV population, which is more involved in the social debate through the community life and the increased risk of stigmatization. Our results are summarized in the memorandum and consent form presented in the Appendices. One issue still open to discussion is the way the results of genetic data will be given to the patients. This work should allow other researchers and members of evaluation committees to enrich their considerations and should stimulate discussion on this topic.

PubMed Disclaimer

References

    1. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. [published erratum appears in Science 1996 Nov 15;274(5290):1069] Science. 1996;273:1856–1862. - PubMed
    1. Meyer L, Magierowska M, Hubert JB, Rouzioux C, Deveau C, Sanson F, et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS. 1997;11:F73–78. - PubMed
    1. Spear BB. Viewpoint – Pharmacogenomics: Today, Tomorrow and Beyond. Drug Benefit Trends. 1999;11:53–54.
    1. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. QJM. 2000;93:391–423. - PubMed
    1. Brockmoller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnosis of cytochrome P450 polymorphisms in clinical development and in drug treatment. Pharmacogenomics. 2000;1:125–151. - PubMed

Publication types